Click Here
Publications & Posters

Research that inspires, data that informs, and knowledge that empowers.

We are proud to contribute to latest immunology and inflammation research through scientific publications and medical meetings.

September 2025

WEBINAR: EADV Late-Breaker Presentation of EVO756 Phase 2 Data in Chronic Inducible Urticaria

Evommune Company Presentation
Presented at the European Academy of Dermatology and Venereology (EADV) Congress 2025

September 2025

EVO756: An Oral MRGPRX2 Blocker Targeting Mast Cell-Neuron Signaling for Multiple Chronic Inflammatory Diseases

Amanda Jacobson, Sreya Bagchi, Alexandra Pavel, Claudia Montlollor-Abalate, Janice Drew, Polina Bukshpun, Kelsey Santisteban, Dan Burge, Jamie Harden, Jeegar Patel, Theodore J. Price , Lorena Riol-Blanco
Presented at the Cell Symposia: Neuro-immune axis: Charting the periphery meeting (New York City, NY), 2025

June 2025

EVO756: A Promising Oral MRGPRX2 Inhibitor Showing Strong Preclinical and Phase 1 Results

Jamie Harden, Sreya Bagchi, Alexandra Pavel, Claudia Montlollor-Abalate, Andrea Kim, Janice Drew, Polina Bukshpun, Kelsey Santisteban, Dan Burge, Jeegar Patel, Lorena Riol-Blanco
Presented at the Federations of Clinical Immunological Societies (FOCIS) annual meeting (Boston, MA), 2025

May 2025

EVO756: An Emerging Oral MRGPRX2 Blocker with Compelling Data from Early Studies

Jamie Harden, Sreya Bagchi, Alexandra Pavel, Claudia Montlollor-Abalate, Andrea Kim, Janice Drew, Polina Bukshpun, Kelsey Santisteban, Dan Burge, Jeegar Patel, Lorena Riol-Blanco
Presented at the Society of Investigative Dermatology (SID) (San Diego, CA), 2025

May 2025

EVO756 potently blocks MRGPRX2-mediated mast cell activation as well as MRGPRX2 and IgE-dependent synergistic responses

Sreya Bagchi, Claudia M. Albalate, Alexandra Pavel, Jeegar Patel, Lorena R. Blanco, Jamie Harden
Presented at the Annual Meeting of American Association of Immunologist: IMMUNOLOGY2025 (Honolulu, Hawai'i)

December 2024

EVO756, an oral MRGPRX2 antagonist, is well-tolerated and demonstrates target engagement: Results from a Phase 1 Study

Sarbjit S. Saini, MD, Kelly Devine, RN, BSN, CCRP, Tahira Mirza, MBBS, CCRP, Kristin L. Chichester, MS, Janice Drew, MPH, Polina Bukshpun, Kelsey Santisteban, Dan Burge, MD
Presented at the 7th GA²LEN Global Urticaria Forum (Berlin, Germany), 2024

December 2024

EVO756 inhibits activation of MRGPRX2 in several in vitro models and correlates to human in vivo data

Sreya Bagchil, Jeegar Patel, Lorena Riol Blanco, Jamie L. Harden
Presented at the 7th GA²LEN Global Urticaria Forum (Berlin, Germany), 2024

May 2024

Transcriptional profiling of primary human-skin derived mast cell activation by various MRGPRX2 agonists and inhibition with EVO756

Sreya Bagchi, Jeegar Patel, Lorena Riol Blanco, Jamie L. Harden
Presented at American Association of Immunology (AAI), 2024

November 2023

EVO756 is a novel MRGPRX2 antagonist that potently inhibits human mast cell degranulation in response to multiple agonists – a potential treatment for CSU and beyond


Jamie L. Harden, Jelle Folkerts, See-Ying Tam, Stefan Frischbutter, Magda Babina4, Hans E. Hofland, Jeegar P. Patel, Marcus Maurer, and Stephen J. Galli
Presented at the Inflammatory Skin Disease Summit, 2023

November 2023

Role of MRGPRs in substance P signaling, itch, and mast cell activation

Yanek Jiménez-Andrade, Lilah Gmyrek, Jamie Harden, Jeegar Patel, Hans Hofland, Jin Mo Park, and Ethan A. Lerner

Presented at the World Congress on Itch, 2023

We have a range of chronic inflammatory disease programs currently in development.

See our pipeline